FIELD: pharmaceutics.
SUBSTANCE: invention relates to certain compounds having structures specified below. The invention also relates to pharmaceutical composition based on the specified compounds and to a method for increasing the activity of cystic fibrosis transmembrane conductance regulator (hereinafter – CFTR).
EFFECT: technical result is obtaining new quinolone derivatives useful for increasing the activity of cystic fibrosis transmembrane conductance regulator (CFTR).
or 
10 cl, 1 tbl, 35 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ARGINASE INHIBITORS AND THERAPEUTIC USE THEREOF | 2011 |
|
RU2586219C2 |
| MONOACYLGLYCEROL LIPASE MODULATORS | 2019 |
|
RU2797323C2 |
| BICYCLIC LACTAMS AND METHODS FOR USE THEREOF | 2016 |
|
RU2716136C2 |
| COMPOUNDS, COMPOSITIONS AND METHODS FOR INCREASING CFTR ACTIVITY | 2015 |
|
RU2767460C2 |
| ANILIDES OF AMINO ACIDS AS LOW-MOLECULAR MODULATORS IL-17 | 2019 |
|
RU2815505C2 |
| COMPOSITIONS AND METHODS OF TREATING ANDROGEN-RECEPTOR-POSITIVE CANCER | 2020 |
|
RU2817802C2 |
| DERIVATIVES OF PYRIDINE AND APPLICATION THEREOF AGAINST MICROBACTERIA | 2015 |
|
RU2664587C1 |
| ISOINDOLINONE INHIBITORS OF MDM2-P53 INTERACTION WITH ANTI-CANCER ACTIVITY | 2016 |
|
RU2794333C1 |
| CALPAIN MODULATORS AND THEIR THERAPEUTIC USE | 2017 |
|
RU2773288C2 |
| COMPOUNDS AND METHODS FOR ENHANCING DEGRADATION OF TARGET PROTEINS AND OTHER POLYPEPTIDES, USING E3 UBIQUITIN LIGASE | 2013 |
|
RU2781452C2 |
